<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04545658</url>
  </required_header>
  <id_info>
    <org_study_id>PTOP-RT (29BRC20.0154)</org_study_id>
    <nct_id>NCT04545658</nct_id>
  </id_info>
  <brief_title>Prediction of Esophageal and Lung Toxicities After Radiation (Chemo) Therapy</brief_title>
  <acronym>PTOP-RT</acronym>
  <official_title>Prediction of Esophageal and Lung Toxicities After Radiation (Chemo) Therapy for Lung Cancer Management</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Brest</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Brest</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      (Chemo)-radiotherapy is the gold standard therapeutic treatment for patients with locally&#xD;
      advanced lung cancer non accessible or ineligible for surgery. While some progress occurred&#xD;
      regarding progression free survival and overall survival thanks to recent advances (i.e.,&#xD;
      durvalumab), prediction of pulmonary and esophageal toxicity, remains insufficiently&#xD;
      accurate. Current dose-volume histograms (DVH) do not account for spatial dose distribution&#xD;
      and strict application of current dose constraints does not prevent toxicity events in some&#xD;
      of the treated patients. The goal of this work was to investigate the added predictive value&#xD;
      of the radiomics approach applied to dose maps regarding acute and late toxicity in both&#xD;
      lungs and the esophagus.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 16, 2020</start_date>
  <completion_date type="Actual">July 31, 2020</completion_date>
  <primary_completion_date type="Actual">July 31, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Prediction of Acute Pulmonary Toxicity</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>The model's performance will be evaluated based on the observed rate of Acute Pulmonary Toxicity using classification metrics (area Under the curve, balanced accuracy).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Prediction of Late Pulmonary Toxicity</measure>
    <time_frame>Between 6 months and 2 years after radiotherapy</time_frame>
    <description>The model's performance will be evaluated based on the observed rate of Late Pulmonary Toxicity using classification metrics (area Under the curve, balanced accuracy).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Prediction of Acute Oesophageal Toxicity</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>The model's performance will be evaluated based on the observed rate of Acute Oesophageal Toxicity using classification metrics (area Under the curve, balanced accuracy).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Prediction of Late Oesophageal Toxicity</measure>
    <time_frame>Between 6 months and 2 years after radiotherapy</time_frame>
    <description>The model's performance will be evaluated based on the observed rate of Late Oesophageal Toxicity using classification metrics (area Under the curve, balanced accuracy).</description>
  </primary_outcome>
  <enrollment type="Actual">167</enrollment>
  <condition>Lung Cancer</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Stage I, II, III lung cancer patients treated with (chemo)-radiotherapy&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients treated by (chemo)-radiotherapy for a primary lung cancer by radiotherapy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Incomplete treatment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <location>
    <facility>
      <name>CHRU Brest</name>
      <address>
        <city>Brest</city>
        <state>Finist√®re</state>
        <zip>29200</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>August 10, 2020</study_first_submitted>
  <study_first_submitted_qc>September 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 11, 2020</study_first_posted>
  <last_update_submitted>September 10, 2020</last_update_submitted>
  <last_update_submitted_qc>September 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

